FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1710-1712 June 22, 1995 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Over the past 20 years, the results of well-designed randomized trials in patients with deep-vein thrombosis have provided reliable information about the treatment of this common disorder. Patients with deep-vein thrombosis should receive adequate doses of heparin for a minimum of five days.^1,2,3 When heparin is stopped, patients should continue to receive oral anticoagulant therapy; the incidence of recurrent deep-vein thrombosis in the first three months is over 25 percent without such treatment, but less than 4 percent among treated patients.^4,5

Progress has been made in determining the optimal intensity of oral anticoagulant therapy,⁶ but the optimal duration of treatment . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Campbell, I A, Bentley, D P, Prescott, R J, Routledge, P A, Shetty, H G M, Williamson, I J (2007). Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 334: 674-674 [Abstract] [Full Text]  
• Huisman, M. V., van der Meer, F. J.M., van Rooden, C. J., Malik, V., Kupfer, Y., Tessler, S., Tran, H. A., Brotman, D. J., Ridker, P. M., Goldhaber, S. Z., Glynn, R. J., Kearon, C., Julian, J. A., Ginsberg, J. S., Buller, H. R., Prins, M. H. (2003). Low-Intensity versus Conventional-Intensity Warfarin for Prevention of Recurrent Venous Thromboembolism. NEJM 349: 2164-2167 [Full Text]  
• van Dongen, C. J.J., Prins, M. H., Buller, H. R., Seneviratne, C., Kupfer, Y., Tessler, S., Krishnan, J. A., Streiff, M. B., Cosmi, B., Palareti, G., Aberegg, S. K., Ridker, P. M., Goldhaber, S. Z., Glynn, R. J., the PREVENT Investigators, (2003). Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. NEJM 349: 398-400 [Full Text]  
• (2003). British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 58: 470-483 [Full Text]  
• Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41: 1633-1652 [Full Text]  
• Ridker, P. M, Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., Paulson, R., Wong, T., Bauer, K. A., Schwartz, B. A., Miletich, J. P., Bounameaux, H., Glynn, R. J., the PREVENT Investigators, (2003). Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. NEJM 348: 1425-1434 [Abstract] [Full Text]  
• Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation 107: 1692-1711 [Full Text]  
• Eckman, M. H., Erban, J. K., Singh, S. K., Kao, G. S. (2003). Screening for the Risk for Bleeding or Thrombosis. ANN INTERN MED 138: W-15-W-24 [Abstract] [Full Text]  
• Eckman, M. H., Singh, S. K., Erban, J. K., Kao, G. (2002). Testing for Factor V Leiden in Patients with Pulmonary or Venous Thromboembolism: A Cost-Effectiveness Analysis. Med Decis Making 22: 108-124 [Abstract]  
• Hirsh, J., Bates, S. M. (2001). Clinical Trials That Have Influenced the Treatment of Venous Thromboembolism: A Historical Perspective. ANN INTERN MED 134: 409-417 [Abstract] [Full Text]  
• Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., Deykin, D. (2001). Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. Chest 119 : 8S-21S [Full Text]  
• Schafer, A. I. (1999). Venous Thrombosis as a Chronic Disease. NEJM 340: 955-956 [Full Text]  
• Prandoni, P., Lensing, A. W., Prins, M. R (1998). Long-term outcomes after deep venous thrombosis of the lower extremities. Vasc Med 3: 57-60 [Abstract]  
• Ridker, P. M, PREVENT Investigators, (1998). Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Vasc Med 3: 67-73 [Abstract]  
• Crowther, M., Hirsh, J. (1998). Low-Molecular-Weight Heparin for the Out-of-Hospital Treatment of Venous Thrombosis: Rationale and Clinical Results. PERSPECT VASC SURG ENDOVASC THER 9: 91-98 [Abstract]  
• Morris, T. A., Marsh, J. J., Konopka, R., Pedersen, C. A., Chiles, P. G., Fagnani, R., Hagan, M., Moser, K. M. (1997). Antibodies Against the Fibrin ß-Chain Amino-Terminus Detect Active Canine Venous Thrombi. Circulation 96: 3173-3179 [Abstract] [Full Text]  
• Hirsh, J., Hoak, J. (1996). Management of Deep Vein Thrombosis and Pulmonary Embolism : A Statement for Healthcare Professionals From the Council on Thrombosis (in Consultation With the Council on Cardiovascular Radiology), American Heart Association. Circulation 93: 2212-2245 [Full Text]  
• Ridker, P. M., Miletich, J. P., Stampfer, M. J., Goldhaber, S. Z., Lindpaintner, K., Hennekens, C. H. (1995). Factor V Leiden and Risks of Recurrent Idiopathic Venous Thromboembolism. Circulation 92: 2800-2802 [Abstract] [Full Text]  
• Safavi, K., Shojania, A. M., Schulman, S., The Duration of Anticoagulation Trial Study Group, , Hirsh, J., The Duration of Anticoagulation Trial Study Group, (1995). Duration of Anticoagulant Therapy for Venous Thrombosis. NEJM 333: 1288-1289 [Full Text]  
• Chesterman, C N (1995). After a first episode of venous thromboembolism. BMJ 311: 700-701 [Full Text]  
• (1995). Optimal Duration of Anticoagulation for Thromboembolism. Journal Watch Cardiology 1995: 3-3 [Full Text]